SELLAS Life Sciences Group, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
SELLAS Life Sciences Group, Inc. (SLS) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $797.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-19
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $797.00K.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $622.00K.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $613.00K.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $229.00K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $797.00K 10-K · filed 2026-03-19 | |
| 2024-12-31 | $622.00K 10-K · filed 2026-03-19 | |
| 2023-12-31 | $613.00K 10-K · filed 2025-03-20 | |
| 2022-12-31 | $229.00K 10-K · filed 2024-03-28 | |
| 2021-12-31 | $140.00K 10-K · filed 2023-03-16 | |
| 2020-12-31 | $75.00K 10-K · filed 2022-03-31 | |
| 2019-12-31 | $2.06M 10-K · filed 2021-03-23 | |
| 2018-12-31 | $2.22M 10-K · filed 2020-03-13 | |
| 2017-12-31 | $2.55M 10-K · filed 2019-03-22 | |
| 2016-12-31 | $28.00K 10-K · filed 2018-04-13 | $5.76M 10-K · filed 2017-03-15 |
| 2015-12-31 | $5.05M 10-K · filed 2017-03-15 | |
| 2014-12-31 | $4.68M 10-K/A · filed 2016-04-15 | |
| 2013-12-31 | $8.32M 8-K · filed 2015-12-04 | |
| 2012-12-31 | $7.94M 10-K · filed 2014-03-17 | |
| 2011-12-31 | $6.88M 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |